Analyst Price Targets — CORT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 20, 2026 11:05 am | — | H.C. Wainwright | $67.00 | $34.24 | TheFly | Corcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright |
| January 23, 2026 11:49 am | — | Canaccord Genuity | $100.00 | $41.30 | TheFly | Corcept Therapeutics price target raised to $100 from $99 at Canaccord |
| January 22, 2026 5:41 pm | Swayampakula Ramakanth | H.C. Wainwright | $105.00 | $41.47 | TheFly | Corcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright |
| January 2, 2026 11:34 am | Swayampakula Ramakanth | H.C. Wainwright | $90.00 | $36.35 | StreetInsider | Corcept Therapeutics (CORT) PT Lowered to $90 at H.C. Wainwright |
| January 2, 2026 11:22 am | Edward Nash | Canaccord Genuity | $99.00 | $36.90 | StreetInsider | Corcept Therapeutics (CORT) PT Lowered to $99 at Canaccord Genuity |
| December 31, 2025 6:05 pm | — | Truist Financial | $50.00 | $34.25 | TheFly | Corcept Therapeutics price target lowered to $50 from $135 at Truist |
| December 31, 2025 2:50 pm | — | Wolfe Research | $30.00 | $33.12 | TheFly | Corcept downgraded to Underperform at Wolfe after CRL for relacorilant |
| December 16, 2025 10:11 am | Ashwani Verma | UBS | $95.00 | $87.30 | TheFly | Corcept Therapeutics initiated with a Neutral at UBS |
| September 10, 2025 12:28 pm | — | Canaccord Genuity | $140.00 | $71.62 | TheFly | Corcept Therapeutics price target raised to $140 from $137 at Canaccord |
| May 6, 2025 1:57 pm | Joon Lee | Truist Financial | $135.00 | $70.74 | TheFly | Corcept Therapeutics price target lowered to $135 from $150 at Truist |
Latest News for CORT
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A…
PHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) -- Corcept Therapeutics, Inc. (NASDAQ: CORT): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
LOS ANGELES, March 2, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who…
LOS ANGELES, March 2, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept " or "the Company") (NASDAQ: CORT ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CORT during the class…
New York, New York--(Newsfile Corp. - March 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"). A class action lawsuit has already been filed.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CORT.
U.S. House Trading
No House trades found for CORT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.